Follow The Filings

AMLX Amylyx Pharmaceuticals Inc.

Health Care, filed as AMYLYX PHARMACEUTICALS INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by AMLX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AMLX insider trades
  • $152K bought by 1 insider
  • None no sales outside a trading plan
  • $1.4M sold by 2 insiders under 10b5-1 plans
  1. George M Milne Jr. Director
    Planned sale
    $831K 30,000 shares at $27.70 3.7% of stake
    Traded Oct 5 Filed Oct 7
    ↗
  2. Gina Mazzariello Chief Legal Officer
    Planned sale
    $539K 30,000 shares at $17.96 14% of stake
    Traded Jul 9–10 Filed Jul 13
    ↗
  3. Karen Firestone Director
    Buy
    $51K 3,800 shares at $13.51 +6% to stake
    Traded May 21 Filed May 26
    ↗
  4. Karen Firestone Director
    Buy
    $101K 8,100 shares at $12.45 +15% to stake
    Traded Dec 23, 2025 Filed Dec 23, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 28 sales to cover taxes, 10 stock grants, 6 option exercises, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 1.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $380.79M $87.37M $0M
Gross profit * $355.34M $81.42M $0M
Gross margin * 93.3% 93.2% —
Net income $49.27M -$301.74M -$144.74M
Net margin * 12.9% -345.4% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $464.67M $189.43M $323.67M
Total non-current assets * $52.79M $4.2M $8.97M
Total assets $517.45M $193.63M $332.64M
Total current liabilities $82.04M $28.41M $22.69M
Total non-current liabilities * $1.98M $0.463M $4.7M
Total equity $433.43M $164.76M $305.26M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $11.92M -$167.65M -$123.34M
Cash from investing $92.05M $75.65M $14.04M
Cash from financing $3.54M $0.348M $257.03M
Net change in cash $107.68M -$92.08M $148.8M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.